Because MDSCs promote both ovarian cancer cell stemness and accumulation of ascites in ovarian cancer via STAT3 (172), we propose that targeting STAT3 along with CD44 in ovarian tumors may be a rational strategy for blocking MDSC-driven immunosuppression and enhancing the efficacy of conventional ovarian cancer therapy. The gene discussed is CD44; the disease is ovarian cancer.